mol42
11 Feb 2017
bit of info from[link] immunoassays rely on antibodies that provide high affinity, specificity and selectivity against a target analyte. However, the use of antibodies for the detection of small-sized, non-immunogenic targets, such as pharmaceuticals and environmental contaminants presents a number of challenges. Recent advances in protein engineering have led to the emergence of antibody mimetics that offer the high affinity and specificity associated with antibodies but with reduced batch-to- batch variability, high stability and in vitro selection to ensure rapid discovery of binders against a wide range of targets. In this work we explore the potential of Affimers, a recent example of antibody mimetics, as suitable bio-receptors for the detection of small organic target compounds, here methylene blue. Target immobilisation for Affimer characterisation was achieved using long-chained alkanethiol linkers coupled with oligoethyleneglycol (LCAT-OEG). Using quartz crystal microbalance with dissipation monitoring (QCM-D), we determine the affinity constant, KD , of the methylene blue Affimer to be comparable to that of antibodies. Further, we demonstrate the high selectivity of Affimers for its target in complex matrices, here a limnetic sample. Finally, we demonstrate an Affimer-based competition assay, illustrating the potential of Affimers as bioreceptors in immunoassays for the detection of small-sized, non-immunogenic compounds.unfortunately just abstract available as only accepted for publication 01/02/17 onlinebit re journal here[link]
Ripley94
08 Feb 2017
Re: Finncap Thank you proverbs 26.. I was not aware of that.
mol42
06 Feb 2017
Growth&Innovation Forum 2017-31/01/17 Presentation here[link]
mol42
01 Feb 2017
BIO 2017 San Diego we're there as is apparently our ex PM[link]
mol42
01 Feb 2017
Hardman Feb 17 ExtractComprehensive review of progress in 2016Avacta is the proprietary owner of Affimer technology for the development of bio-therapeutics, diagnostic tests and research reagents. Affimers represent a revolutionary alternative to the established antibody technology which dominates the drug industry despite its limitations. Avacta has made considerable progress towards its strategic goal to have a first-in-man Affimertherapeutic by the end of 2019. Meanwhile, its reagent business is continuing to deliver on three initial areas of strategic focus. There will be greater recognition of the long-term potential of Affimers in the enterprise value as Avacta signs more licensing/collaboration deals.Strategy:To commercialise its Affimer technology through a combination of bespoke research and diagnostic tools, collaborative deals and by developing its own proprietary therapeutic Affimer lead compounds. With ca.£17m on deposit, the company has the resource to deliver on its stated strategy.AGM update:Management provided a comprehensive update for investors on the company’s progress and achievements in fiscal 2016 at its AGM. There is clearly an increasing awareness and level of interest in Affimer technology as evidenced by the multiple paid-for ongoing evaluations and collaborations.Therapeutics:In just 12 months, Avacta has identified its first Affimer leads, completed animal efficacy and pharmacokinetic studies, both with positive outcomes, expanded its immuno-oncology pipeline, and commenced immunogenicity studies which are expected to complete during 2017.Partnerships:Avacta continues to see progress with its declared partners using Affimers for new reagents, diagnostics and bio-pharmaceuticals. Collaborators that undertook early custom Affimer evaluations are increasingly returning with multiple repeat orders, which may lead to potential licensing deals. Investment summary:The enterprise value of Avacta does not reflect the value that big pharma is prepared to pay for disruptive technologies and assets. Several recent deals have reaffirmed the median up-front payments in the order of US$17m and US$40m for pre-clinical and Phase I assets respectively. Licensing deals for both therapeutics and reagent assets will further validate the technology, as will moving an Affimer therapeutic into man.Other companies and featured article available below[link]
mol42
27 Jan 2017
Re: Global Discovery and at pegs 2017 - no surprise[link]
mol42
27 Jan 2017
Global Discovery not yet on website but here in may[link] note discussions on promexus on other boards you heard it here first and whilst you may not remember....tis drivel elsewhereaccording to our latest tweets today biotech pharma led to 30 leadswe await news re revenue stream derived therefromanyway still heremol
mol42
23 Jan 2017
AGM Slides available[link] can expect a lot of newsflow throughout 2017 then!latest trading update also encouraging - albeit revenue in next trading update and 2017 year end results especially will provide clearer evidence of the way forwardstill heremol
mol42
23 Jan 2017
AS Interview 230117 [link]
Proverbs 26 vs 5
14 Jan 2017
Re: Finncap what does Corporate mean? see[link] they'll issue a 'corporate' rating if the company in question is a corporate client of theirs - i.e. the broker is paid a fee for providing services to the company, as a retainer or whatever.It may be perceived to be a conflict of interest to be issuing ratings on companies which pay you fees (some might point out that it may be difficult to stay objective - would you issue a sell on a company which gives you a lot of business?), so they don't express an opinion and just call it a 'corporate'.
mol42
12 Jan 2017
Finncap I know they are our joint broker and nomad but as at 09/01/17recently noted as ‘Reiterates’ with the recommendation being set at ‘CORPORATE’ today by analysts at finnCap. Target sp 200p - as before methinks - their capitals in corporate btwinterview here in dec 16 by mark brewer - we are towards the end[link] a bit of infobw all - hopefully a great year for usmol
mol42
11 Jan 2017
Hardman Jan 17 monthlyExpanding opportunities for Affimers Avacta is the proprietary owner of Affimer technology for the development of bio-therapeutics, diagnostic tests and research reagents. Affimers represent a revolutionary alternative to the established antibody technology which dominates the drug industry despite its limitations. Avacta has made considerable progress towards its strategic goal to have a first-in-man Affimer therapeutic by the end of 2019. Meanwhile, its reagent business is continuing to deliver on three initial areas of strategic focus. There will be greater recognition of the long-term potential of Affimers in the enterprise value as Avacta signs more licensing/collaboration deals.Strategy:To commercialise its Affimer technology through a combination of bespoke research tools, collaborative deals and by identifying and developing its own proprietary therapeutic Affimer lead compounds. With ca.£17m on deposit, the company has the resource to deliver on its stated strategy.Therapeutics:In 12 months, Avacta has identified its first Affimer leads for potential bio-therapeutics in the fast moving field of immune-oncology, completed animal studies showing that the drug is well tolerated and demonstrated efficacy (reduction in tumour growth) in an animal model.Affinity separation:Used extensively in the biotech industry to purify biological molecules from complex mixtures, the competitive advantages of Affimers over existing technologies were presented at bioProcess UK in November 2016.The affinity separation market is worth an estimated $0.5bn p.a.CAR-T cell therapy:In November, Avacta announced a research collaboration with Memorial Sloan Kettering Cancer Center to develop Affimers that bind to CD 19 antigens which play a role in clinical oncology. Consequently, several companies are targeting CD 19 antigens in their drug development programmes.Investment summary:The enterprise value of Avacta does not reflect the value that big pharma is prepared to pay for disruptive technologies and assets. The median up-front paid is US$17m and US$40m for pre-clinical and Phase I assets respectively. Licensing deals for both therapeutics and reagent assets will further validate the technology, as will moving an Affimer therapeutic into man. Avacta will update the market on progress at its AGM on 20th January.we await an update prior to the 20th then hopefullymol
paulmc1
10 Jan 2017
Avacta tipped today Noticed that Avacta was tipped in an e-newsletter today as one of their stronger tips for 2017. I don't have details as it's a subscription tipster service but it hasn't exactly set the sp on fire 
Milltig
16 Dec 2016
Re: blog 151216 
perhaps that explains the recent movement in the share price!!Here's hoping for better.
mol42
15 Dec 2016
Re: blog 151216 mind i suppose it is coming close to the silly season!mol
